Preferred Label : FGFR4 Antagonist INCB062079;
NCIt synonyms : Fibroblast Growth Factor Receptor 4 Antagonist INCB062079; FGFR4 Inhibitor INCB062079;
NCIt definition : An orally bioavailable, selective inhibitor of human fibroblast growth factor receptor
4 (FGFR4), with potential antineoplastic activity. Upon oral administration, FGFR4
antagonist INCB062079 specifically and irreversibly binds to the cysteine residue
at position 552 (Cys 552) that is within the active site of FGFR4. This blocks FGFR4
autophosphorylation and activation of receptor tyrosine kinase activity that would
normally occur after binding to its ligand fibroblast growth factor 19 (FGF19), which
both inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation
in FGF19- and FGFR4-overexpressing cells. FGFR4, a receptor tyrosine kinase, is involved
in angiogenesis and in the proliferation, differentiation, and survival of tumor cells.
FGFR4 expression is associated with poor prognosis. FGF19 is overexpressed by certain
tumor cell types.;
Molecule name : INCB62079; INCB 062079; INCB-062079;
NCI Metathesaurus CUI : CL541447;
Origin ID : C143067;
UMLS CUI : C4688504;
Semantic type(s)
- concept_is_in_subset
- has_target
